Stock analysis, AI verdict, fundamentals & technical signals
Rating: NEUTRAL
Price: $62.03 Analyst target: $117.30 Upside: 89.10%
Vaxcyte, Inc., a pre-clinical biotech vaccine company, develops novel vaccines to prevent or treat infectious diseases globally. The company is headquartered in Foster City, California.
See the full interactive analysis & chart →Informational only — not investment advice.